Goodwill and Other Intangible Assets

The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the three months ended December 31, 2018:



(in thousands)	Pharmaceutical Distribution Services			Other			Total
Goodwill as of September 30, 2018	$	4,852,775		$	1,811,497		$	6,664,272
Goodwill recognized in connection with acquisitions	—			35,871			35,871
Purchase price accounting adjustments	(512		)	—			(512		)
Foreign currency translation	—			(2,084		)	(2,084		)
Goodwill as of December 31, 2018	$	4,852,263		$	1,845,284		$	6,697,547

The following is a summary of other intangible assets:



	December 31, 2018								September 30, 2018
(in thousands)	Weighted Average Remaining Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite-lived trade names		$	685,260	$	—		$	685,260	$	685,380	$	—		$	685,380
Finite-lived:
Customer relationships	14 years	2,550,198		(592,800		)	1,957,398		2,549,245		(555,440		)	1,993,805
Trade names and other	12 years	418,568		(136,528		)	282,040		397,946		(129,303		)	268,643
Total other intangible assets		$	3,654,026	$	(729,328	)	$	2,924,698	$	3,632,571	$	(684,743	)	$	2,947,828

Amortization expense for finite-lived intangible assets was $47.1 million and $40.2 million in the three months ended December 31, 2018 and 2017, respectively. Amortization expense for finite-lived intangible assets is estimated to be $185.8 million in fiscal 2019, $178.7 million in fiscal 2020, $174.8 million in fiscal 2021, $173.2 million in fiscal 2022, $172.2 million in fiscal 2023, and $1,402.0 million thereafter.

As a result of the continued suspension of production activities at PharMEDium Healthcare Holdings, Inc.'s ("PharMEDium") largest compounding facility located in Memphis, Tennessee (see Note 13), the Company updated its recoverability assessment of PharMEDium's long-lived assets as of December 31, 2018. The recoverability assessment was based upon comparing its undiscounted cash flows to the carrying value of the PharMEDium asset group, excluding goodwill. The carrying value of the asset group was $849 million as of December 31, 2018. The Company concluded that PharMEDium's long-lived assets are recoverable as of December 31, 2018; however, the forecasted undiscounted cash flows used to perform the recoverability assessment are inherently uncertain and include assumptions, such as the timing of resumed production activities and profitability, that could differ from actual results in future periods.